Drugs for the treatment of glaucoma: Targets, structure-activity relationships and clinical research

Xianbo Wu,Xinwei Yang,Qi Liang,Xiali Xue,Jianli Huang,Jie Wang,Yihua Xu,Rongsheng Tong,Maoyu Liu,Qiaodan Zhou,Jianyou Shi

DOI: https://doi.org/10.1016/j.ejmech.2021.113842

IF: 7.088

2021-12-01

European Journal of Medicinal Chemistry

Abstract:Glaucoma is the third leading cause of blindness and impairment of vision worldwide, after refractive errors and cataracts. According to the survey, the number of people with glaucoma is more than 76 million, with projections increasing to 112 million by 2040. With the coming of an aging society, the number of people suffering from glaucoma will increase day by day. Glaucoma is a heterogeneous disease characterized by damage to the head of the optic nerve and visual field. High intraocular pressure is a major risk and cause of glaucoma optic neuropathy. Therefore, drug lowering intraocular pressure therapy is still the first-line therapy in clinical practice. Here, the targets, structure-activity relationship, and clinical progress of drugs for the treatment of glaucoma are reviewed.

chemistry, medicinal